Another potent selective PFKFB3 inhibitor, PFK158, is the first PFKFB3 inhibitor being approved by the U.S. Food and Drug Administrator (FDA) to undergo clinical trial in patients with various malignancies including ovarian, prostate, lung, melanoma, breast and pancreatic cancers (http://www.advancedcancertherapeutics.com). Here, PFKFB3 is linked to pancreatic neoplasm.